~~[X]~~ ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

~~[ ]~~ ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such fling requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and ~~"emerging~~“emerging growth ~~company"~~company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of ~~November 13, 2019,~~May 19, 2020, the Registrant had outstanding 71,661,656 shares of its $0.01 par value Common Stock.

The accompanying notes are an integral part of these consolidated financial statements.

For the Three Month Period Ended March 31, 2020 (unaudited) and at December 31, 2019

The accompanying notes are an integral part of these consolidated financial statements.

- 4 -

ADVANZEON SOLUTIONS, INC.

CONSOLIDATED STATEMENTS OF ~~OPERATIONS~~CASH FLOWS

For the Three ~~and Nine~~ Month Periods Ended ~~September 30,~~March 31, 2020 and 2019 ~~and 2018~~ (unaudited)

Three-Month Period Ended Nine-Months Period Ended
September 30, September 30,
2019 2018 2019 2018
Revenues:
Obstructive sleep apnea (OSA) $ 68,173 $ 99,083 $ 226,549 449,650
Total revenues 68,173 99,083 �� 226,549 449,650
Costs and expenses:
Costs of revenues 2,394 46,028 110,211 280,372
General and administrative 428,077 409,419 1,269,920 1,396,478
Depreciation and amortization 84 149 524 449
Total costs and expenses 430,555 455,596 1,380,655 1,677,299
Loss from operations (362,382 ) (356,513 ) (1,154,106 ) (1,227,649 )
Other income (expense):
Interest expense (383,798 ) (307,922 ) (1,052,991 ) (1,148,795 )
Interest income 29 —   6,023 —
Legal settlement —   —   112,172 328,269
State tax penalty (1,650 ) —   (1,650 ) —
Extinguishment of loan due to shareholder —   —   —   7,771,140
Settlement of prior accounting services —   —   —   (240,000 )
Other income —   —   —   2,380
Total other income (expense) (385,419 ) (307,922 ) (936,446 ) 6,712,994
Income taxes —   —   —   —
Net (loss) income $ (747,801 ) $ (664,435 ) $ (2,090,552 ) $ 5,485,345
PER SHARE INFORMATION
Net (Loss) Income Per Common Share $ (0.01 ) $ (0.01 ) $ (0.03 ) $ 0.08
Weighted Average Number of Common
Shares Outstanding 67,361,656 66,661,656 67,140,411 65,849,175

	Three Month Periods Ended
	March 31,
	2020			2019

CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(928,346	)	$	(727,761	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		311			205
Stock issued for services		-			16,000
Amortization of right of use assets		45,059			12,087
Net changes in assets and liabilities:
Accounts receivable		(17,571	)		3,251
Other current assets		159,515			(172,296	)
Payments on lease liabilities		(45,059	)		(12,087	)
Accounts payable		124,621			138,528
Other accrued expenses		430,084			363,948
Net cash used in operating activities		(231,386	)		(378,125	)

CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property, plant, and equipment		(5,067	)		(1,549	)
Net cash used in investing activities		(5,067	)		(1,549	)

CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from promissory notes		182,000			355,000
Sale of stock		-			15,000
Net cash provided by financing activities		182,000			370,000

Net decrease in cash		(54,453	)		(9,674	)

CASH - Beginning of Year		69,327			25,036

CASH - END OF PERIOD	$	14,874		$	15,362

Supplemental disclosures of cash flow information:
Cash paid during the period for:
Interest	$	-		$	-
Income taxes	$	-		$	-

Recording of right of use assets under lease agreements (ASU 2016-02)	$	-		$	119,640

The accompanying notes are an integral part of these consolidated financial statements.

- 5 -

ADVANZEON SOLUTIONS, INC.

~~CONSOLIDATED STATEMENT OF STOCKHOLDERS’ DEFICIENCY~~

~~For the Nine Month Period Ended September 30, 2019 (unaudited) and December 31, 2018~~

Series C Series C
Convertible Convertible Common
Preferred Preferred Stock Common Additional
Stock Number Stock Stock Number Stock Paid-in Accumulated
of Shares Amount of Shares Amount Capital Deficit Total

Balance at December 31, 2018 10,434 $ 10 66,661,656 $ 666,617 $ 28,012,007 $ (54,581,873 ) $ (25,903,239 )

Stock issued for services —   —   200,000 2,000 14,000 —   16,000

Sale of stock —   —   500,000 5,000 10,000 —   15,000

Net loss —   —   —   —   —   (2,090,552 ) (2,090,552 )

Balance at September 30, 2019 10,434 $ 10 67,361,656 $ 673,617 $ 28,036,007 $ (56,672,425 ) $ (27,962,791 )

~~The accompanying notes are an integral part of these consolidated financial statements.~~

~~ADVANZEON SOLUTIONS, INC.~~

~~CONSOLIDATED STATEMENTS OF CASH FLOWS~~

~~For the Nine Month Periods Ended September 30, 2019 and 2018 (unaudited)~~

Nine Month Periods Ended
September 30,
2019 2018
CASH FLOWS FROM OPERATING ACTIVITIES
Net (loss) income $ (2,090,552 ) $ 5,485,345
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Depreciation and amortization 524 449
Stock issued for services 16,000 240,000
Extinguishment of loan due to shareholder
   and accrued interest —   (7,771,140 )
Amortization of right of use assets 62,135 —
Net changes in assets and liabilities:
Accounts receivable (281 ) (34,493 )
Other current assets (1,525,858 ) (700,842 )
Payments on lease liabilities (62,135 ) —
Accounts payable 431,114 520,379
Contingent liability —   152,664
Accrued interest - related party —   (246,568 )
Other accrued expenses 1,119,373 1,328,842
Net cash used in operating activities (2,049,680 ) (1,025,364 )
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property, plant, and equipment (1,549 ) —
Net cash used in investing activities (1,549 ) —
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from promissory notes 2,100,250 1,079,223
Payments on debt (25,000 ) —
Sale of stock 15,000 —
Net cash provided by financing activities 2,090,250 1,079,223
Net increase in cash 39,021 53,859
CASH - Beginning of Year 25,036 18,200
CASH - END OF PERIOD $ 64,057 $ 72,059
Supplemental disclosures of cash flow information:
Cash paid during the period for:
Interest $ 6,960 $ —
Income taxes $ —   $ —
Recording of right of use assets under
lease agreements (ASU 2016-02) $ 390,260 $ —
Schedule of non-cash investing transactions:
Convertible promissory note converted to common stock $ —   $ 51,231

~~The accompanying notes are an integral part of these consolidated financial statements.~~

~~ADVANZEON SOLUTIONS, INC.~~

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1.	DESCRIPTION OF THE COMPANY’S BUSINESS AND BASIS OF PRESENTATION

The consolidated financial statements include the accounts of Advanzeon Solutions, Inc and its wholly owned subsidiary, and its respective subsidiaries (collectively referred to herein as, the “Company,” “Advanzeon,” “we”, “us,” or “our”).

In the opinion of management, the accompanying unaudited financial statements contain all adjustments necessary to present fairly the ~~Company's~~Company’s financial position as of December 31, ~~2018,~~2019, the changes therein for the three ~~and nine~~ month periods then ended and the results of operations for the three ~~and nine~~ month periods ended ~~September 30, 2019~~March 31, 2020 and ~~2018.~~2019.

The financial statements included in the Form 10-Q are presented in accordance with the requirements of the Form and do not include all of the disclosures required by accounting principles general accepted in the United States of America. For additional information, reference is made to the ~~Company's~~Company’s annual report on Form 10-K for the ~~fiscal~~ year ended December 31, ~~2018,~~2019, filed ~~May 24, 2019.~~April 9, 2020. The results of operations for the three ~~and nine~~ month periods ended ~~September 30,~~March 31, 2020 and 2019 ~~and 2018,~~ are not necessarily indicative of operating results for the full year.

2.	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Established in 1969, Advanzeon Solutions, Inc., (formerly Comprehensive Care Corp.) (“Advanzeon”, “we”, “Parent”, or the “Company”), through its wholly-owned subsidiary Pharmacy Value Management Solutions, Inc.,(“PVMS”) and its wholly-owned subsidiaries during 2015, and partly in 2016, provided managed care services by acting as the administrator for certain administrative service agreements in the behavioral health and substance abuse fields. We primarily offered these services to commercial, Medicare, Medicaid, Children’s Health Insurance Program (“CHIP”) health plans, as well as self-insured companies. Our managed care operations consisted solely of servicing administrative service agreements. Starting in July of 2015, we implemented our comprehensive sleep apnea program, called “SleepMaster Solutions” ™. SleepMaster Solutions (“SMS”) utilizes an administrative system for the convenient identification/testing and therapy of Obstructive Sleep Apnea (“OSA”). We partnered with a national health care provider by initiating a sleep apnea wellness program whereby we screened, tested and when needed, offered treatment programs for treating this disorder. We also contracted with a union to treat its driver members. Beginning in 2017, our only business was our SMS sleep apnea program.

The Company has elected to not adopt the option available under United States generally accepted accounting principles (“GAAP”) to measure any eligible financial instruments or other items at fair market value at this time. Accordingly, the Company measures all of its assets and liabilities on the historical cost basis of accounting, except as otherwise required by GAAP.

Inter-company accounts and transactions have been eliminated in consolidation. Certain minor reclassifications of prior period amounts have been made to conform to the current period presentation.

Use of Estimates - The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts. Actual results could differ from these estimates. Estimates involved in the determination of an allowance for doubtful accounts receivable are considered by management as particularly susceptible to material change in the next year. Other significant estimates relate to stock-based compensation, warrants and beneficial conversion features.

- 6 -

ADVANZEON SOLUTIONS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Accounts Receivable - Accounts receivable is carried at its estimated collectible value. Since customer credit is generally extended on a short-term basis, accounts receivable does not bear interest and are uncollateralized. We manage credit risk and determine necessary allowances by evaluating customers’ credit worthiness before extending credit and periodically for collectability, based primarily on customers’ past credit history and current financial conditions and general economic conditions, results of prior collection efforts, the relative strength of our relationship therewith and, in the event of a dispute, its legal position and the estimated cost of proposed collection proceedings. Management has not established a policy for when to charge off uncollectible accounts receivable or to use external collection agencies and makes such decisions on a case-by-case basis. The maximum losses that the Company would incur if a customer failed to pay would be limited to the carrying value of the receivable.

Revenue Recognition- ~~The~~In accordance with FASB ASC Topic 606, "Revenue from contracts with customers", the Company ~~is on an accrual basis and~~recognizes revenue ~~is recognized~~ when ~~billed, which is approximately~~obligations under the terms of a contract with the customer are satisfied. Generally, this occurs upon shipment of the CPAP to their customer or when the ~~testing service~~test is ~~performed or CPAP machine is shipped.~~performed.

Property and Equipment - Property and equipment, as described in Note 4, is stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives ranging from 2 to 12 years.

Leasehold Improvement - Leasehold improvement, as described in Note 5, is stated at cost less accumulated amortization. Leasehold improvements are amortized over the shorter of the lease term or the asset’s useful life.

Fair Value Measurements - The carrying amounts of cash, accounts receivable and accounts payable approximate their estimated fair value due to the short-term nature of these instruments. Since our other financial liabilities are not traded in an open market, we generally use a present value technique, which is a level 3 input, as defined in GAAP, to measure the estimated fair value of these financial instruments, except for valuing stock options and warrants (see below). The rate used for discounting expected cash flows is a risk-free rate adjusted for systematic and unsystematic risk.

The carrying amounts of long-term debt and estimated fair values of the attached warrants at ~~September 30, 2019~~March 31, 2020 and December 31, ~~2018~~2019 are as follows:

	September 30, 2019				December 31, 2018				March 31, 2020				December 31, 2019
			Estimated				Estimated				Estimated				Estimated
			Fair Value of				Fair Value of				Fair Value of				Fair Value of
	Carrying		Attached		Carrying		Attached		Carrying		Attached		Carrying		Attached
	Amount		Warrants		Amount		Warrants		Amount		Warrants		Amount		Warrants

Convertible promissory notes	$	7,375,173	$	—	$	5,299,923	$	—	$	7,746,173	$	-	$	7,564,173	$	-
Short term notes payable	$	4,788,016	$	—	$	4,788,016	$	—		4,788,016		-		4,788,016		-
Loan payable related party		444,920		—		737,023		—		257,729		-		342,670		-
	$	12,608,109	$	—	$	10,824,962	$	—	$	12,791,918	$	-	$	12,694,859	$	-

During the ~~nine~~three month period ended ~~September 30, 2019,~~March 31, 2020, there have been 474 additional convertible notes issued totaling ~~$2,100,250 and one note paid off totaling $25,000.~~$182,000.

- 7 -

ADVANZEON SOLUTIONS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Cost of Revenues- Costs of services consist of supplies and operating expenses. Supplies are recognized in the period in which a patient actually receives the supplies.

Right of Use Assets and Lease Liabilities - During the quarter ended March 31, 2019, the Company implemented Accounting Standards Update 2016-02, Leases. Under the new guidance, a lessee must record a liability for lease payments (referred to as the lease liability) and an asset for the right to use the leased asset during the lease term (referred to at the right of use asset) for all leases, regardless of whether they are designated as finance or operating leases. This election requires the lessee to recognize lease expense on a straight-line basis over the lease term. The right of use assets and corresponding right of use liabilities have been recorded using the present value of the leases. See Notes 10 and 11 within the financial statement for additional disclosure on leases.

Income Taxes - We are subject to the income tax jurisdictions of the U.S. and multiple state tax jurisdictions. However, our provisions for income taxes for ~~2018~~2020 and 2019 include only state income taxes.

Management has evaluated our tax positions taken or to be taken on income tax returns that remain subject to examination (i.e., tax years ~~2016~~2017 and thereafter federally), and has concluded that there have been no uncertain tax positions (as defined in GAAP) taken that require recognition or disclosure in the consolidated financial statements. In the event of any income tax-related interest or penalties are incurred, they would be included in general and administrative expense.

Stock Options and Warrants - We grant stock options and warrants to our employees, non-employee directors, note holders and certain consultants allowing them to purchase our common stock pursuant to approved terms. The estimated value of the warrants issued with debt instruments is recorded as a discount on notes payable and amortized as interest expense over the term of the notes using the effective interest method.

3.	OTHER CURRENT ASSETS

Other current assets consists of the following at ~~September 30, 2019~~March 31, 2020 and December 31, ~~2018:~~

September 30, 2019 December 31, 2018

Due from escrow account $ 1,918,898 $ 472,788
Loans to others 22,459 —
Security deposit 5,500 13,500
Capitalized portion of lease 2,094 2,951
Prepaid expenses 71,394 5,248
Miscellaneous receivable 334,509 334,509

Other current asset $ 2,354,854 $ 828,996

2019:

	March 31, 2020		December 31, 2019

Loans to others	$	34,406	$	42,676
Security and lease deposits		3,500		3,500
Capitalized portion of lease		1,523		1,808
Prepaid expenses		301,319		452,953
Miscellaneous receivable		326,334		325,660

Other current asset	$	667,082	$	826,597

- 8 -

ADVANZEON SOLUTIONS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

4.	PROPERTY AND EQUIPMENT

Property and equipment, net, consists of the following at ~~September 30, 2019~~March 31, 2020 and December 31, ~~2018:~~2019:

September 30, 2019 December 31, 2018

Property and equipment $ 1,549 $ —
Less accumulated depreciation (225 ) —
Property and equipment - net $ 1,324 $ —

	March 31, 2020			December 31, 2019

Property and equipment	$	6,616		$	1,549
Less accumulated depreciation		(621	)		(310	)
Property and equipment - net	$	5,995		$	1,239

Depreciation expense for the ~~nine~~three month periods ended ~~September 30,~~March 31, 2020 and 2019 is $311 and ~~2018 is $225 and $0,~~$56, respectively. A ~~computer~~laptop was acquired in ~~February~~January of ~~2019.~~2020.

5.	LEASEHOLD IMPROVEMENT

Leasehold improvement, net, consists of the following at ~~September 30, 2019~~March 31, 2020 and December 31, ~~2018:~~2019:

September 30, 2019 December 31, 2018

Leasehold improvements $ 2,992 $ 2,992
Less accumulated amortization (2,992 ) (2,693 )
Leasehold improvements - net $ — $ 299

	March 31, 2020			December 31, 2019

Leasehold improvements	$	2,992		$	2,992
Less accumulated amortization		(2,992	)		(2,992	)
Leasehold improvements - net	$	-		$	-

Amortization expense for the ~~nine~~three month periods ended ~~September 30,~~March 31, 2020 and 2019 is $0 and ~~2018 is $299 and $449,~~$149, respectively.

6.	RELATED PARTY LOANS PAYABLE

The Company has received financing from Management of the Company as well as from members of our Board of Directors. These individuals are deemed to be related parties to the Company and their indebtedness must be disclosed separately.

As of ~~September 30, 2019~~March 31, 2020 and December 31, ~~2018,~~2019, there are the following related party notes payable:

September 30, 2019 December 31, 2018

Related party loans payable $ 444,920 $ 737,023

	March 31, 2020		December 31, 2019

Related party loans payable	$	257,729	$	342,670

- 9 -

ADVANZEON SOLUTIONS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

DEBT

As of ~~September 30, 2019~~March 31, 2020 and December 31, ~~2018,~~2019, the balance was as follows:

September 30, 2019 December 31, 2018

Notes payable $ 12,163,189 $ 10,087,939

	March 31, 2020		December 31, 2019

Notes payable	$	12,534,189	$	12,352,189

During the ~~nine~~three month period ended ~~September 30, 2019,~~March 31, 2020, there have been 474 additional convertible-promissory notes totaling $2,100,250. One $25,000 convertible promissory note was repaid with interest of $6,960 during the third quarter 2019. One previous $50,000 convertible-promissory note was converted into stock during the year ended December 31, 2018.$182,000.

Break-out of debt between the parent company and our subsidiary PVMS is as follows:

	September 30, 2019		December 31, 2018		March 31, 2020		December 31, 2019

Advanzeon parent	$	5,010,016	$	5,010,016	$	5,010,016	$	5,010,016
PVMS		7,153,173		5,077,923		7,524,173		7,342,173
	$	12,163,189	$	10,087,939	$	12,534,189	$	12,352,189

At PVMS, the total of notes issued year-to-date and their dollar values were as follows:

September 30, 2019 December 31, 2018

Number of notes issued 47 31

Dollar value $ 2,100,250 $ 1,751,923

	March 31, 2020		December 31, 2019

Number of notes issued		4		51

Dollar value	$	182,000	$	2,289,250

All debt ~~are~~is short-term in nature, one-year maturity date. All debt issued has a stated interest rate of 12% per year.

8.	CONTINGENT LIABILITY

Contingent liability consisted of 3 items:

aA lawsuit against the Company for $450,000 from the son of a deceased promissory note holder. This matter has been dismissed twice by the judge but is ongoing due to appeals. This case ~~should~~is anticipated to expire in June or July for lack of prosecution.

~~interest~~Interest payable in the amount of $171,247 to the same person listed in (1). This interest is related to the lawsuit ~~reference~~referenced in (1).

Advanzeon won a decision on a court case against Universal Healthcare. The ~~attorney's~~attorney’s fees relating to this matter total $21,412. This fee will be paid out of the proceeds of the case when collected.

- 10 -

ADVANZEON SOLUTIONS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

As of ~~September 30, 2019~~March 31, 2020 and December 31, ~~2018,~~2019, the balance of this indebtedness is as follows:

September 30, 2019 December 31, 2018

Disputed note payable $ 450,000 $ 450,000
Disputed interest payable 171,247 171,247
Pending attorney fees 21,412 21,412

Total contingent liability $ 642,659 $ 642,659

	March 31, 2020		December 31, 2019

Disputed note payable	$	450,000	$	450,000
Disputed interest payable		171,247		171,247
Pending attorney fees		21,412		21,412

Total contingent liability	$	642,659	$	642,659

9.	OTHER ACCRUED LIABILITIES

As of ~~September 30, 2019~~March 31, 2020 and December 31, ~~2018,~~2019, the balance of other accrued liabilities is as follows:

	September 30, 2019		December 31, 2018		March 31, 2020		December 31, 2019

Management compensation	$	8,873,802	$	8,873,802	$	8,873,802	$	8,873,802
Accrued interest non-related party		5,839,509		4,809,644		6,347,826		5,956,368
Board of Director fees		1,012,500		900,000		1,087,500		1,050,000
State fees		—		21,000		-		2,800
Payroll liabilities		3,725		2,927		3,803		-
Accrued wages and related		4,609		7,399
Other accrued liabilities						8,940		8,817
Total other accrued debt	$	15,734,145	$	14,614,772	$	16,321,871	$	15,891,787

10.	RIGHT OF USE ASSETS

The Company entered into two leases for office space and one automobile lease ~~prior to the end of the quarter ended September 30, 2019~~ that are classified as right of use assets and lease liabilities. The lease for the Company’s office spaces expire in April 2020 and June 2022. The lease for the automobile expires in June 2021. As the implicit interest rate is not readily identifiable in the leases, the Company calculated the present a value of the leases using the average commercial real estate interest rate of 5.50% at the commencement of the office leases and the interest rate of 2.99% for the automobile lease. Applying the commercial rate, the Company calculated the present value of ~~$361,223~~$294,203 for the office leases and $29,037 for the automobile leasing, that are being amortized over the life of the leases.

- 11 -

ADVANZEON SOLUTIONS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

As of ~~September 30, 2019,~~March 31, 2020, the right of use assets associated with future operating leases are as follows:

Total present value of right of use assets
under lease agreements $ 390,260

Amortization of right of use assets (94,064 )

Total right of use assets as of September 30, 2019 $ 296,196

Total present value of right of use assets under lease agreements	$	323,240

Amortization of right of use assets		(107,508	)

Total right of use assets as of March 31, 2020	$	215,732

Total amortization expense related to the right of use assets under the lease agreements was ~~$62,135~~$45,059 and $0$12,087 for the ~~nine~~three month periods ended ~~September 30,~~March 31, 2020 and 2019, ~~and 2018,~~ respectively.

11.	RIGHT OF USE LEASE LIABILITIES

As disclosed in Note 10, the Company entered into two leases for office space and automobile lease ~~prior to the quarter ended September 30, 2019~~ that are classified as right of use assets and lease liabilities.

As of ~~September 30, 2019,~~March 31, 2020, the lease liabilities associated with future payments due under the leases are as follows:

Total present value of future lease payments $ 390,260

Principal payments made as of the quarter
ended September 30, 2019 (94,064 )

Total right of use lease liabilities as of September 30, 2019 $ 296,196

Total present value of future lease payments	$	323,240

Principal payments made as of the quarter ended March 31, 2020		(107,508	)

Total right of use lease liabilities as of March 31, 2020	$	215,732

The following is a schedule of future minimum lease payments under the right of use lease agreements together with the present value of the net minimum lease payments as of ~~September 30, 2019:~~

Total future minimum lease payments $ 317,251

Less present value discount 21,055

Total right of use lease liabilities as of September 30, 2019 296,196

Less current portion due within one year 124,311

Long-term right of use liabilities $ 171,885

March 31, 2020:

Total future minimum lease payments	$	229,376

Less present value discount		13,644

Total right of use lease liabilities as of March 31, 2020		215,732

Less current portion due within one year		94,410

Long-term right of use liabilities	$	121,322

- 12 -

ADVANZEON SOLUTIONS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

Total maturities of lease liabilities as of ~~September 30, 2019~~March 31, 2020 are as follows:

	Total future
	minimum lease		Present value		Right of use
	payments		discount		lease liabilities
2020	$	103,639	$	9,229	$	94,410
2021		101,095		4,191		96,904
2022		24,642		224		24,418
	$	229,376	$	13,644	$	215,732

Total future
minimum lease Present value Right of use
payments discount lease liabilities
2020 $ 136,858 $ 12,547 $ 124,311
2021 $ 106,330 $ 6,839 $ 99,491
2022 74,063 1,669 72,394
$ 317,251 $ 21,055 $ 296,196

12.	COMMON STOCK

During the ~~nine~~three month period ended ~~September 30,~~March 31, 2020, the Company has not issued any shares.

During the three month period ended March 31, 2019, the Company issued 700,000 shares of its common stock as follows:

On March 21, 2019, the Company issued 200,000 shares of its common stock to its Securities Exchange Commission counsel, who elected to take common stock in the Company as partial payment of its legal fees. The total value shares were valued at $0.08 per share on the total value of $16,000.

Additionally, on March 29, 2019, the Company issued 500,000 shares of its common stock to an existing shareholder and warrant holder, who elected to exercise his warrants to purchase 500,000 shares of the ~~Company's~~Company’s common stock for $15,000. The warrants were issued during May of 2017 for $0.03 per share.

During the nine month period ended September 30, 2018, the Company issued 2,000,000 shares of common stock for a legal settlement. The shares were issued at a value of $0.12 per share or for a total value of $240,000. In addition, the Company issued 1,597,971 shares for the conversion of a promissory note of $50,000 and accrued interest of $1,231. The stock was issued at a value of $0.03 per share. The Company relied on Section 4(a)(2) of the Securities Act of 1933, as amended, as the exemption from registration under the Act.

13.	LEGAL PROCEEDINGS

The Company previously reported that the litigation between Rotech Healthcare, Inc. and Pharmacy Value Management Solutions, Inc. settled. The Company rejected the draft settlement terms and continues to aggressively defend this litigation.

Except as disclosed above and in Item 1, all of the legal proceedings for the ~~nine-month~~three month period ended ~~September 30, 2019,~~March 31, 2020, are disclosed in our annual report on Form10-K for the year ended December 31, ~~2018,~~2019, filed on ~~May 24, 2019.~~April 9, 2020.

- 13 -

ADVANZEON SOLUTIONS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

14.	SUBSEQUENT EVENTS

In accordance with ASC Topic 855, “Subsequent Events”, the Company evaluated subsequent events through ~~November 13, 2019,~~May 19, 2020, the date these financial statements were available to be issued. During its evaluation, the following subsequent events were identified:

Issuance of debt and warrants

Subsequent to the balance sheet date, the Company has issued ~~$139,000~~$109,180 of convertible-promissory notes. All of the debt matures in ~~2020~~2021 and has a stated interest rate of ~~12%~~10% and is unsecured. Concurrent with the issuance of debt, the Company has issued ~~4,128,000~~196,058 warrants at an average exercise price of ~~$0.15~~$0.23 At the time of issuance, all warrants had a three or five year term.

On April 27, 2020, the Company filed a report on Form 8-K regarding our entry into a material definitive agreement and the creation of a direct financial obligation which report is hereby incorporated herein by reference.

~~Stock issued~~Agreements

On May 13, 2020, we entered into an Exchange Agreement (the “Agreement”) with certain holders of our 10% Senior Debt Due April 15, 2012 (collectively, the “Noteholders”). The Agreement provides that the Noteholders with Notes, totaling $2,916,869 of principal and accrued but unpaid interest, exchange their Notes for ~~services~~

~~The Company issued 4,300,000~~14,584,350 shares of ~~restricted common~~the Company’s Common Stock and 5,121,105 Common Stock purchase warrants. The exchange rate was $0.20 per share, which was the market price of the Common Stock as of April 21, 2020. The warrants are for a term of five years and the exercise price is $0.25 per share. The Agreement further provides that the Noteholders lock-up their acquired shares until the earlier of (a) one year from the date of the Agreement, or (b) the average daily trading volume of the Company’s Common Stock is no less than 500,000 shares for 30 consecutive trading days (collectively, the “Lock-up Period”). Following the Lock-up Period and for a period of 18 months from the date of the Agreement, if the Noteholders intend to sell more than 200,000 shares on any single trading day, the Noteholders shall give the Company prior notice of the amount of shares they intend to sell and the Company shall have a right to purchase all, but not less than all, of the offered shares at the closing bid price of the Common Stock on the date of the notice. The Agreement is in further implementation of the Company’s strategy to position the Company for the relisting of its securities on a national stock toexchange such as the ~~investment banker, D. H. Blair Investment Banking Corp. The services were valued at $473,000~~New York Exchange, the American Exchange or ~~$0.11 per share.~~NASDAQ.

- 14 -

ADVANZEON SOLUTIONS, INC.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

General

The following information should be read in conjunction with the financial statements and notes thereto and in conjunction with Managements’ Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the fiscal year ended December 31, ~~2018.~~2019.

This report includes forward-looking statements, the realization of which may be affected by certain important factors discussed previously above under Item 1A, “Risk Factors.”

Overview

The Company through its wholly owned subsidiary Pharmacy Value Management Solutions, Inc. administers and operates a medically driven sleep apnea program branded SleepMaster Solutions™ (“SMS”). Management believes that SMS is the largest provider of these combined services in the nation. We are in all 50 states and provide a turnkey solution designed to effectively keep drivers on the road with no down time, compliant with DOT regulations, improve their health, and significantly decrease legal liability risk for the employer. We are vertically integrated, and we provide a “Program” of services that addresses all the needs of a corporate transportation system, union or other driver-related organizations. We believe we are the only company capable of providing the full range of needed services in a timely manner.

Our services start with the identification of the target population and the potential risk the client currently has. We can do this through our SMS Program, which includes the ability to screen every driver to identify if signs and symptoms of sleep apnea are present. We can then take this data and provide the employer with a list of those drivers that should be tested and the statistical likelihood of the percentage of those drivers who will test positive for obstructive sleep apnea (OSA). Together with the employer/union, SMS provides a realistic time frame, actual total cost, and process for testing all drivers who need to be tested. For those drivers testing positive for OSA, we then provide the appropriate treatment such that the driver will meet the DOT requirements and remain on the road. We monitor 365 days per year driver’s usage of the treatment device according to DOT standards and we report that usage to all stakeholders as required/permitted. We utilize mathematical algorithms to determine if the driver is predicatively meeting the annual DOT requirements for usage. Using those predictive algorithms, we reach out to those drivers and provide case management, encouragement designed to solve problems such that the driver increases usage, if necessary, and remains compliant.

PVMS constructed its model based upon the foregoing principles. The SMS Program includes all processes attended in sleep apnea screening, testing, treatment, monitoring and overall management of commercial drivers’ as well as their employers’ needs. We have successfully established relationships with national health care clinic providers, all with certified medical examiner (“CME”) status. These clinics total almost 1,000 throughout the U.S. We also have both formal and informal relationships with employers; municipalities; a significant veteran’s group; union and non-union driving organizations; suppliers of home sleep testing equipment and a variety of OSA treatment devices; and, a national network of telemedicine sleep specialists covering all 50 states. We have an internal medical team for governance and protocol purposes and a customer service department that interfaces directly with our drivers. We also have a marketing team that regularly interfaces with our existing accounts and markets our services to potential new accounts. Our services are performed utilizing a best medical practices model and an efficient, cost-effective delivery system. We obtain the required equipment on a per order basis from a durable medical equipment distributor.

- 15 -

ADVANZEON SOLUTIONS, INC.

Revenue is recognized when billed, which is approximately when the testing service is performed, or CPAP machine is shipped.

~~During~~

The first quarter of 2020 saw the ~~nine-month period ending September 30, 2019, we continued to work with Concentra Health Services, Inc. toward~~beginnings of a dramatic shift in the ~~implementation~~economic business structure of the ~~program whereby the Company will serve as one~~U.S., ultimately resulting in substantial nationwide business closures and employee layoffs/furloughs. Unemployment went from a low of ~~three~~3.6% to over 14% in April 2020 – an almost overnight shift. All of ~~Concentra’s preferred national sleep apnea services providers. Concentra did not roll out~~ this service until the middle of October. At the time of the roll out we were informed by Concentra that they anticipated the roll out would start slow and progressively build as their centers get used to the new process. As a result, our revenue for the period was not what we had expected. During the period the Company did see revenues coming from other third-party payor accounts that had been established in prior periods. These accounts include unions, municipalities, school districts and small to mid-size corporations-all authorizing the Company to bill them directly for providing our sleep apnea services to their members/employees. Subsequent to the period we announced the establishment of a relationship with All Aboard America, a part of All Aboard America Holdings, Inc., the fourth largest motor coach operator in North America. The Company will screen, test and treat all of its drivers and employees for sleep apnea via our SMS program. We expect to see an increase in our revenues during the fourth quarter as a result of the rapid spread of COVID-19. Caught up in the business closures during a national “stay at home” directive, were a significant number of Concentra clinics. During this same period, the federal government, specifically the Department of Transportation (“DOT”), suspended the need for interstate commercial drivers to report for previously mandated DOT physical exams and lifted the commercial drivers’ driving time restrictions. While the Company is substantially dependent upon the commercial drivers’ need for these physical exams, their attendance at various Concentra clinics for these exams and the referral of the drivers by these clinics to the Company when sleep apnea is suspected, these closures and the suspension of the DOT physical exams did not adversely impact on the Company as much as might have been anticipated. The company was well positioned to withstand these events and had established itself securely enough with both the still open Concentra clinics and new business accounts to maintain its referral momentum, albeit not at the same pace.

The Company’s sales in January 2020 were up 74% compared to its sales in January 2019. The Company’s sales in February 2020 increased 101% over its sales in February 2019. The Company’s overall sales during the first quarter of 2020 increased over 88%. This increase resulted largely from the Company’s senior management’s positioning with senior management of Concentra, its sales reps’ strategic restarting of their regional contacts with Concentra clinic managers and the hiring of additional customer service representatives, adding depth to an already solid rep force. The Company’s growth over 2019 has continued into the second quarter of 2020 with current sales being up an additional 7% over last year’s comparable period. It is also notable that during the first quarter of 2020, approximately 7% of the Company’s increased sales over the comparable period of 2019 were occasioned by relationships established by the Company at the end of 2019 with new third-party payers such as The Pacific Gas & Electric Company (PG&E); the United States Postal Service in Indianapolis, Indiana; a West Coast-based Workers’ Compensation organization with substantial national accounts; and the Transit Authority in Baltimore, Maryland. We expect our ~~existing~~growth pattern to continue in 2020 as the Company spends more time encouraging these new accounts to utilize the Company’s services, exclusively, and as relationships ~~and other potential accounts we are currently working to establish.~~

~~Three month periods ended September 30,~~established by the Company with labor in the latter part of 2019 and ~~2018~~into 2020 mature and strengthen.

Additionally, the Company would note that while its staff was offered the choice of working from home or at the Company’s offices, 100% of the Company’s employees elected to work from the Company’s offices. Thus, notwithstanding the fact that many of the Company’s accounts were not reachable, either personally or by phone, during the first quarter of 2020, the Company’s staff diligently pursued those contacts and new accounts in a coordinated effort to maintain and increase the Company’s business.

- 16 -

ADVANZEON SOLUTIONS, INC.

While a number of labor-related programs were put on hold during the first quarter of 2020, the Company elected to engage in a modified launch of its program with CoreChoice. In March of 2020, the Company prepared for this launch to a limited number of CoreChoice facilities (350 clinics). This launch occurred in late April 2020, and while revenues have not yet commenced from these clinics, management fully expects same to occur within the next 30 – 45 days as the CoreChoice clinics reopen.

In addition, the Company hired two senior labor consultants whose directive is to enhance our sales revenue from the Western Teamsters Welfare Trust Fund, a long-standing Company account, and increase the Company’s revenue through new accounts from the labor/union market.

Additionally, the Company accelerated the development of its CPAP sanitizing device and daily sanitizing wipes product line (see our announcement of April 13, 2020). In April 2020, we commenced taking orders for this product line and first deliveries to our customers are expected to occur by the end of May. The Company’s sales reps market our sanitizer and sanitizing wipes products in tandem with sales of the Company’s CPAP device.

The Company believes that its sales activities will shortly place the Company in a position to move forward with its expressed intent to relist the Company on NASDAQ. In the first quarter of 2020, the Company commenced activities aimed at reducing Company debt, much of which existed with the Company for decades. In the second quarter of 2020, the Company successfully negotiated with debt holders holding debt against the Company of approximately $2.9 million to convert that debt into Common Stock of the Company (equity). Additionally, the Company has received commitments to convert another approximately $7 million of debt into equity of the Company. The Company intends to pursue these efforts with the goal of ultimately converting much, if not all, of the Company’s long-standing debt (as opposed to continuing operation expenses) into equity in the Company, bringing it one step closer to its “up-listing” goal.

Sources of Revenue

A quantitative summary of our revenues by source category for the three month periods ended ~~September 30, 2019~~March 31, 2020 and ~~2018:~~2019:

2019 2018 Change

OSA- related $ 68,173 $ 99,083 $ (30,910 )
2020 2019 Change

OSA- related $ 127,548 $ 67,923 $ 59,625
Results of Operations
OSA services ~~decreased~~increased to ~~$68,173~~$127,548 in ~~2019~~2020 from ~~$99,083~~$67,923 in ~~2018.~~2019. The ~~decrease~~increase was primarily the result of the timing of the Concentra launch. ~~Earlier in the~~Last year, on May 14, 2019, we reached an agreement with Concentra whereby Concentra engaged the Company, and the Company accepted the engagement, to serve as Concentra’s preferred national sleep apnea services provider. The launch by Concentra of this program ~~which~~ included notifying all of the Concentra clinics of ~~same,~~same. The launch was delayed so that same launched much later than anticipated. Pending the launch, we were asked by Concentra, albeit informally, to cease activities in terms of having our regional representative’s visit the various Concentra clinics promoting our sleep apnea services to said clinics. We honored that request, and in so honoring the request, our sales were diminished. The launch occurred in mid-October and we were informed by Concentra that they anticipated the roll out would start slowly and progressively build as their centers get used to the new process. Nonetheless, as a result of the Concentra launch and the Pinnacle agreement, as described below, we expect to see an increase in revenuebut was initiated during the fourth quarter of 2019.
Cost of revenues ~~decreased~~increased to $64,909 in 2020 from ~~$46,028 in 2018 to $2,394~~$41,660 in 2019 due to ~~a decrease~~an increase in ~~sales and a settlement agreement from a previous supplier reducing the cost of sales by $34,400.~~sales.
19
- 17 -

ADVANZEON SOLUTIONS, INC.
General and administrative expense
General and administrative expense in total for the three month periods ended ~~September 30,~~March 31, 2020 and 2019 ~~and 2018~~ was as follows:
2019 $ 428,077
2018 409,419
Change $ 18,658
Percentage Change 4.56 %
2020 $ 596,065
2019 425,804
Change $ 170,261
Percentage Change 39.99 %

We evaluate expenses at the Parent company level as well as at our PVMS subsidiary. Expenses at the Parent company level include overhead and the cost of being a public entity. Expenses at PVMS are solely related to the OSA services segment. A breakdown of these expenses for the three month periods ended ~~September 30,~~March 31, 2020 and 2019 ~~and 2018~~ is as follows:
2019 2018 Change Percent Change

Parent $ 118,096 $ 130,218 $ (12,122 ) -9.31 %
PVMS 309,981 279,201 30,780 11.02 %

Total $ 428,077 $ 409,419 $ 18,658 4.56 %
Percent
2020 2019 Change Change

Parent $ 243,222 $ 196,135 $ 47,087 24.01 %
PVMS 352,843 229,669 123,174 53.63 %

Total $ 596,065 $ 425,804 $ 170,261 39.99 %

Parent Company Level
2019 2018 Change Percent Change

Professional fees $ 34,329 $ 49,735 $ (15,406 ) -30.98 %
Travel expense —   1,500 (1,500 ) -100.00 %
Board of Directors fees 37,500 37,500 —   0.00 %
Rent expense 25,255 25,129 126 0.50 %
Other 21,012 16,354 4,658 28.48 %

Total G & A $ 118,096 $ 130,218 $ (12,122 ) -9.31 %

Percent
2020 2019 Change Change

Professional fees $ 166,376 $ 124,461 $ 41,915 33.68 %
Travel expense 67 3,000 (2,933 ) -97.77 %
Board of Directors fees 37,500 37,500 - 0.00 %
Rent expense 23,181 25,829 (2,648 ) -10.25 %
Other 16,098 5,345 10,753 201.18 %

Total general and administrative $ 243,222 $ 196,135 $ 47,087 24.01 %
Explanations of variations by line item follow:
Travel expense decreased by ~~$1,500~~$2,933 due to main operations moving to the subsidiary level.
Professional fees ~~decreased~~increased by ~~$15,406. The decrease is~~$41,915. There was increase due to a ~~result~~new consulting service expenses in the total of ~~a $18,000 decrease~~$118,000 and an increase of $11,197 in legal fees in the three month period ended ~~September 30, 2019~~March 31, 2020 compared to the three month period ended ~~September 30, 2018.~~March 31, 2019. Audit fees decreased by $63,550 and accounting fees decreased by $19,832 due to the fact that the 2019 10-K was filed in April 2020.
Rent expense has stayed relatively the same.
Other general and administrative expense increased by ~~$4,658.~~$10,753. This increase was due to a new D&O Insurance expense of ~~$16,000~~$12,780 while ~~storage, travel, and marketing decreased by $9,000. Other~~other miscellaneous items decreased by ~~$2,300.~~$2,000.
20
- 18 -

ADVANZEON SOLUTIONS, INC.
PVMS Subsidiary Level
2019 2018 Change Percent Change

Payroll related $ 129,457 $ 141,516 $ (12,059 ) -8.52 %
Travel and related expense 60,048 61,003 (955 ) -1.57 %
Professional fees 53,454 21,550 31,904 148.05 %
Marketing costs 16,511 14,066 2,445 17.38 %
Automobile expense 6,733 5,015 1,718 34.26 %
Office supplies 13,191 13,481 (290 ) -2.15 %
Rent expense 12,941 7,400 5,541 74.88 %
Other 17,646 15,170 2,476 16.32 %

Total G & A $ 309,981 $ 279,201 $ 30,780 11.02 %
Percent
2020 2019 Change Change

Payroll related $ 175,872 $ 102,145 $ 73,727 72.18 %
Travel and related expense 66,165 39,427 26,738 67.82 %
Professional fees 51,792 42,497 9,295 21.87 %
Marketing costs 16,834 7,500 9,334 124.45 %
Automobile expense 7,394 5,561 1,833 32.96 %
Office supplies 2,942 8,859 (5,917 ) -66.79 %
Rent expense 11,837 10,549 1,288 12.21 %
Other 20,007 13,131 6,876 52.36 %

Total general and administrative $ 352,843 $ 229,669 $ 123,174 53.63 %
Explanations of variations by line item follow:
Payroll related expenses ~~decreased $12,059. The Company no longer used 4~~increased $73,727. There are 5 additional subcontractors in the three months ended ~~September 30, 2019~~March 31, 2020 that were used in the comparable period in ~~2018.~~2019.
Travel expense increased by 26,738 due to the company’s increased travel between states.
Professional Fees increase by $9,295. The company hired 5 new consultants to bring in additional revenue.
Marketing costs increased by $9,334. In August 2019, the company hired a new advertising firm to work on the company’s website.
Office supplies decreased by $5,917 due to office supplies were fully stocked going into the new year of 2020.
Rent expense stayed relatively the same.
Professional Fees increased $31,904. This increase is due to the new consulting services expense in the total of $31,500. In January 2019, we hired a law firm to begin litigation against our former accountants.
~~Marketing costs increased by $2,445 due to the increased visits to potential clinics in building up new clientele. In August 2019, we hired a new advertising firm.~~
~~Office supplies stayed relatively the same.~~
Rent expense increased by $5,541. The California office lease began mid-way through the three months period ended June 30, 2018. As of May 2019, the California office lease was renewed for a new monthly rate of $4,000. We pay the California lease payments on a residential unit that we use as an office for our account managers, sales and marketing staff. The unit is also used as a temporary residence for one of our national account managers while developing the West Coast market.
Other general and administrative expense ~~stayed relatively the same.~~increased by $6,876. This is due to revamp of website, employee benefits, and printing and postage for a conference.
- 19 -
ADVANZEON SOLUTIONS, INC.
Interest expense
Interest expense in total for the three month periods ended ~~September 30,~~March 31, 2020 and 2019 ~~and 2018~~ was as follows:
2019 $ 383,798
2018 307,922
Change $ 75,876
Percentage Change 24.64 %

21
2020 $ 394,629
2019 328,015
Change $ 66,614
Percentage Change 20.31 %

~~ADVANZEON SOLUTIONS, INC.~~
A breakdown of the interest expense for the three month periods ended ~~September 30,~~March 31, 2020 and 2019 ~~and 2018~~ is as follows:
2019 2018 Change

Parent $ 172,720 $ 163,092 $ 9,628
PVMS 211,078 144,830 66,248

Total $ 383,798 $ 307,922 $ 75,876
~~Nine-month periods ended~~~~September 30, 2019 and 2018~~
~~Sources of Revenue~~
~~A quantitative summary of our revenues by source category for the nine month periods ended September 30, 2019 and 2018:~~
2019 2018 Change

OSA- related $ 226,549 $ 449,650 $ (223,101 )
~~Results of Operations~~
OSA services decreased to $226,549 in 2019 from $449,650 in 2018. The decrease was primarily the result of the timing of the Concentra launch. Earlier in the year, May 14, 2019, we reached an agreement with Concentra whereby Concentra engaged the Company, and the Company accepted the engagement, to serve as Concentra’s preferred national sleep apnea services provider. The launch by Concentra of this program, which included notifying all of the Concentra clinics of same, was delayed so that same launched much later than anticipated. Pending the launch, we were asked by Concentra, albeit informally, to cease activities in terms of having our regional representative’s visit the various Concentra clinics our sleep apnea services to said clinics. We honored that request, and in so honoring the request, our sales were diminished. The launch occurred in mid-October and we were informed by Concentra that they anticipated the roll out would start slowly and progressively build as their centers get used to the new process. Nonetheless, as a result of the Concentra launch and the Pinnacle agreement, as described below, we expect to see an increase in revenue during the fourth quarter of 2019.
~~Cost of revenues decreased to $110,211 in 2019 from $280,372 in 2018 due to a decrease in sales and a settlement agreement from a previous supplier reducing the cost of sales by $34,400.~~
~~General and administrative expense~~
~~General and administrative expense in total for the nine-month periods ended September 30, 2019 and 2018 was as follows:~~
2019 $ 1,269,920
2018 1,396,478
Change $ (126,558 )
Percentage Change -9.06 %
2020 2019 Change

Parent $ 144,113 $ 163,092 $ (18,979 )
PVMS 250,516 164,923 85,593

Total $ 394,629 $ 328,015 $ 66,614

- 20 -
22

ADVANZEON SOLUTIONS, INC.
We evaluate expenses at the Parent company level as well as at our PVMS subsidiary. Expenses at the Parent company level include overhead and the cost of being a public entity. Expenses at PVMS are solely related to the OSA services segment. A breakdown of these expenses as September 30, 2019 and 2018 is as follows:
Percent
2019 2018 Change Change

Parent $ 470,917 $ 484,377 $ (13,460 ) -2.78 %
PVMS 799,003 912,101 (113,098 ) -12.40 %

Total $ 1,269,920 $ 1,396,478 $ (126,558 ) -9.06 %

~~Parent Company Level~~
Percent
2019 2018 Change Change

Professional fees $ 245,594 $ 213,766 $ 31,828 14.89 %
Travel expense 3,815 25,367 (21,552 ) -84.96 %
Board of Directors fees 112,500 112,500 —   0.00 %
Office supplies 336 3,370 (3,034 ) -90.03 %
Rent expense 76,532 74,736 1,796 2.40 %
Other 32,140 54,638 (22,498 ) -41.18 %

Total general and administrative $ 470,917 $ 484,377 $ (13,460 ) -2.78 %
~~Explanations of variations by line item follow:~~
Professional fees increased by $31,828. The increase is a result of a $53,000 increase in accounting fees, a $56,000 increase in audit fees, a $200 increase in other professional fees, and a $77,000 decrease in legal fees in the nine-month period ended September 30, 2019 compared to the nine-month period ended September 30, 2018.
~~Travel expense decreased by $21,552 due to main operations moving to the subsidiary level.~~
~~Rent expense remained relatively the same.~~
~~Other general and administrative expense decreased by $22,498.~~
~~Office supplies decreased by approximately $3,004 due to the operations moving to the subsidiary level.~~
~~Taxes decreased by approximately $17,000 due to a change in par value.~~
~~Advertising and promotion expense decreased by $8,000 due to marketing efforts moving to the subsidiary level.~~
23
~~ADVANZEON SOLUTIONS, INC.~~
~~PVMS Subsidiary Level~~
Percent
2019 2018 Change Change

Payroll related $ 341,769 $ 408,172 $ (66,403 ) -16.27 %
Travel and related expense 151,372 200,446 (49,074 ) -24.48 %
Professional fees 135,201 83,206 51,995 62.49 %
Marketing costs 33,740 42,296 (8,556 ) -20.23 %
Dues and subscriptions 841 38,557 (37,716 ) -97.82 %
Office supplies 30,768 41,824 (11,056 ) -26.43 %
Rent expense 35,942 11,100 24,842 223.80 %
Other 69,370 86,500 (17,130 ) -19.80 %

Total general and administrative $ 799,003 $ 912,101 $ (113,098 ) -12.40 %
~~Explanations of variations by line item follow:~~
Payroll related expenses decreased $66,403. The Company no longer used 3 subcontractors in the nine-month period ended September 30, 2019 that were used in the comparable period in 2018. There is an increase of $7,000 due to one of the employees receiving a raise in the nine-month period ended September 30, 2019.
Travel expense was $49,074 lower due to the sales force having cutback on traveling to trade shows and visiting existing and potential clinics. The sales force and supporting forces were most active in 2017 in building up new clientele while in 2018 expanding the services offered to current clientele from local to national.
Professional Fees increased $51,995. In January 2018, we hired an outside accountant for PVMS, whom we pay $7,000 per month. For the period January through March 2018 the fee was prorated to $11,000. There were also 2 consultants hired and paid $34,000 to improve social media and miscellaneous in the nine-month period ended September 30, 2018 that were not used in 2019. Legal expense increased by $23,000 due to litigation against our former accountants and former supplier.
Marketing costs decreased by $8,556 due to the sales force having cutback on traveling to trade shows and visiting existing and potential clinics. The sales force and supporting forces were most active in 2017 in building up new clientele while in 2018 expanding the services offered to current clientele from local to national.
~~Dues and Subscriptions comprised, in part, an annual payment to a national organization of $25,000 during the nine-month period of 2018 that is no longer used in the comparable period of 2019.~~
~~Office supplies decreased by $11,056 due to the expense of setting up the California location in 2018.~~
~~Rent expense increased $24,842 due to having a California office lease beginning in June of 2018.~~
Other general and administrative expense decreased by $17,130. This was mainly due to $11,500 in provider fees in 2018 that the Company is no longer using in 2019. In the nine months ended September 30, 2018, the Company had bad debt expense due to cleaning up it's receivables. During 2019, there has been very little bad debt.
24
~~ADVANZEON SOLUTIONS, INC.~~
~~Interest expense~~
~~Interest expense in total for the nine month periods ended September 30, 2019 and 2018 was as follows:~~
2019 $ 1,052,991
2018 1,148,795
Change $ (95,804 )
Percentage Change -8.34 %
~~A breakdown of the interest expense for the nine month periods ended September 30, 2019 and 2018 is as follows:~~Financial Condition

2019 2018 Change

Parent $ 498,905 $ 780,936 $ (282,031 )
PVMS 554,086 367,859 186,227

Total $ 1,052,991 $ 1,148,795 $ (95,804 )
25
~~ADVANZEON SOLUTIONS, INC.~~
~~Financial Condition~~
Liquidity and Capital Resources
During the ~~nine~~three month period ended ~~September 30, 2019,~~March 31, 2020, we funded our operations from revenues and ~~$2,100,250 in private borrowings. During the nine month period ended September 30, 2018, we funded our operations from revenues and $1,079,223~~$182,000 in private borrowings. We will continue to fund our operations from these sources until we are able to produce operating revenue sufficient to cover our cost structure. In the event we are not able to secure such funding, our operations will be adversely affected.
Short Term: We funded our operations with revenues from sales and private borrowings.
~~During~~
Subsequent Events
Subsequent to March 31, 2020, we issued a convertible promissory note in the ~~period in September 2019,~~principal amount of $109,180. The term of the note is 12 months and the interest rate is 10% per annum.
On April 27, 2020, we ~~hired~~filed a ~~person to serve as~~report on Form 8-K regarding our ~~national director~~entry into a material definitive agreement and the creation of ~~sales and marketing.~~ a direct financial obligation which report is hereby incorporated herein by reference.
Agreements
On ~~September 17, 2019,~~May 13, 2020, we entered into an ~~agreement~~Exchange Agreement (the “Agreement”) with ~~D.H. Blair Investment Banking Corp. (“D.H. Blair”~~certain holders of our 10% Senior Debt Due April 15, 2012 (collectively, the “Noteholders”)~~, whereby D.H. Blair will act~~. The Agreement provides that the Noteholders with Notes, totaling $2,916,869 of principal and accrued but unpaid interest, exchange their Notes for 14,584,350 shares of the Company’s Common Stock and 5,121,105 Common Stock purchase warrants. The exchange rate was $0.20 per share, which was the market price of the Common Stock as of April 21, 2020. The warrants are for a ~~financial~~term of five years and ~~business advisor~~the exercise price is $0.25 per share. The Agreement further provides that the Noteholders lock-up their acquired shares until the earlier of (a) one year from the date of the Agreement, or (b) the average daily trading volume of the Company’s Common Stock is no less than 500,000 shares for 30 consecutive trading days (collectively, the “Lock-up Period”). Following the Lock-up Period and for a period of 18 months from the date of the Agreement, if the Noteholders intend to sell more than 200,000 shares on any single trading day, the ~~Company. Included in D.H. Blair’s undertaking is assisting~~Noteholders shall give the Company prior notice of the amount of shares they intend to sell and the Company shall have a right to purchase all, but not less than all, of the offered shares at the closing bid price of the Common Stock on the date of the notice. The Agreement is in ~~conducting a series~~further implementation of ~~transactions designed~~the Company’s strategy to position the Company ~~to list its shares of common stock on The Nasdaq Stock Market. We will attempt to institute a series of corporate actions that will result in a recapitalization of our capital structure. Among~~for the transactions being contemplated are attempting to reduce our stockholder deficiency by among other actions being able to convert a large portion of the accumulated debt to equity and raising more equity through the sale of our securities. As we are able to generate more revenue from operations, which we expect to do in the forthcoming periods, the deficiency should be reduced as well. Additionally, we may seek to institute a reverse common stock split. We can offer no assurances that any of these contemplated steps can be accomplished to the extent necessary to meet the eligibility requirements for listing.
~~Subsequent Events~~
In October, we announced that we had entered into an exclusive contract with Pinnacle National, a leading third party administrator serving union employees. Under the agreement, we will be positioned to screen, test and treat as needed, all Pinnacle National members electing to utilize this service at no cost to the members. All costs will be borne by Pinnacle National. This program will roll out in four segments, the first of which will impact in excess of 150,000 members. The number of members within each subsequent segment will increase. The term of the agreement is three years. We expect the first segment to begin immediately. On May 14, 2019, we entered into an agreement with Concentra Health Services, Inc., which agreement provided, in pertinent part, that Concentra engaged the Company, and the Company accepted such engagement, to serve as “ Concentra’s preferred national sleep apnea Services provider ” That program was launched by Concentra on October 16, 2019, pursuant to which Concentra notified allrelisting of its clinic facilities that the Company, along with two other providers have been designated as Concentra’s preferred providers with respect to sleep apnea services. At the time of the roll out we were informed by Concentra that they anticipated the roll out would start slowly and progressively build as their centers get used to the new process. We received an immediate response in that we started receiving referrals from Concentra clinics with which we had previously not received referrals. Although there can be no assurances, the Company would anticipatesecurities on a substantial increase in its referrals from the Concentra clinics, nationwide. The Company also reached a verbal agreement with Sleep Cycle, a Swedish-based App company that markets an App that it has denominatednational stock exchange such as the ~~“smart alarm clock.” Sleep Cycle’s App is reportedly~~New York Exchange, the largest selling App, worldwide, with over 35 million downloads and in excess of 25 million active users. Through this App, Sleep Cycle collects significant data from its users such that it is probable that when analyzing the data, with the expertise we possess in the sleep apnea field, potential sufferers of sleep apnea can be readily identified. The Company’s agreement with Sleep Cycle is to initially test ours and Sleep Cycle’s theory of being able to identify sufferers of sleep apnea from Sleep Cycle’s existing data, and assuming the theory proves out, the Company and Sleep Cycle will jointly market our testing and treatment capabilities to select groups of Sleep Cycle’s App users. The initial market will be the United States. Existing plans call for the program to launch within the fourth quarter of 2019. Both Sleep Cycle and the Company are optimistic that the theory will prove out, thus providing the platform for the next marketing phase of this project.American Exchange or NASDAQ.
Subsequent to the close of the period ended September 30, 2019 we issued a total of 4,128,000 common stock purchase warrants. we also issued 4,300,000 shares of our restricted common stock to our investment banker, D. H. Blair Investment Banking Corp., as consideration for advisory services and as provided in our Financial and Business Advisory Agreement dated September 17, 2019. The services were valued at $473,000. Additionally, we issued a total of $139,000 in convertible promissory notes.
26

~~ADVANZEON SOLUTIONS, INC.~~
Item 3. Quantitative and Qualitative Disclosures about Market Risk:
As a smaller reporting company, we are not required to make any disclosure.
Item 4. Controls and Procedures
Our management is responsible for establishing and maintaining adequate internal control over our financial reporting. Internal control over financial reporting is a process designed to provide reasonable assurance to our management and board of directors regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles.
Our internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect our transactions; (ii) provide reasonable assurance that transactions are recorded as necessary for preparation of our financial statements; (iii) provide reasonable assurance that receipts and expenditures of company assets are made in accordance with management authorization; and (iv) provide reasonable assurance that unauthorized acquisition, use or disposition of company assets that could have a material effect on our financial statements would be prevented or detected on a timely basis.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because changes in conditions may occur or the degree of compliance with the policies or procedures may deteriorate.
Our management assessed the effectiveness of our internal control over financial reporting as of ~~September 30, 2019.~~March 31, 2020. This evaluation was based on criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission, or COSO, Internal Control-Integrated Framework. Based upon such assessment, our CFO concluded that, as of ~~September 30, 2019,~~March 31, 2020, our internal controls over financial reporting were not optimally effective in the specific areas described in the paragraphs below.

- 21 -
ADVANZEON SOLUTIONS, INC.
As of ~~September 30, 2019,~~March 31, 2020, our CFO identified the following specific material weaknesses in the Company’s internal controls over its financial reporting processes:
Policies and Procedures for the Financial Close and Reporting Process – During the period of this report, the Company’s policies or procedures did not clearly define the roles in the financial reporting process. The various roles and responsibilities related to this process should be defined, documented, updated and communicated. Not having clear policies and procedures in place amounts to a material weakness in the Company’s internal controls over its financial reporting processes.
27● Policies and Procedures for the Financial Close and Reporting Process – During the period of this report, the Company’s policies or procedures did not clearly define the roles in the financial reporting process. The various roles and responsibilities related to this process should be defined, documented, updated and communicated. Not having clear policies and procedures in place amounts to a material weakness in the Company’s internal controls over its financial reporting processes.

● Representative with Financial Expertise – For three month period ended March 31, 2020, the Company did not continuously have an employee with the requisite knowledge and expertise to review the financial statements and disclosures at a sufficient level to monitor the financial statements and disclosures to the Company. Failure to have, continuously, an employee with such knowledge and expertise amounts to a material weakness to the Company’s internal controls over its financial reporting processes.

~~ADVANZEON SOLUTIONS, INC.~~
Representative with Financial Expertise – For nine month period ended September 30, 2019, the Company did not continuously have an employee with the requisite knowledge and expertise to review the financial statements and disclosures at a sufficient level to monitor the financial statements and disclosures to the Company. Failure to have, continuously, an employee with such knowledge and expertise amounts to a material weakness to the Company’s internal controls over its financial reporting processes.
As a result of our retaining the services of an Outside Accountant in January 2018 and appointing an internal Company employee to interface with the Outside Accountant, we have instituted the following policies and procedures designed to address the material weaknesses cited above.
~~All billing invoices prepared by the billing department are sent to the Outside Accountant for review and approval before sending out to the customer.~~
Copies of all incoming payable invoices are sent to the Outside Accountant for review, approval and data entry into the accounting system. That way Corporate Office has the originals and the outside accountants have duplicate copies. Accounts Payable Aging Report is sent once a week from the Outside Accountants to the Corporate office. The Corporate office, along with Outside Accountants, decide on which bills to pay weekly. Electronic payments have a duel control approval system (one person is initiating the payment and another person is approving the payment). We also appointed the principle from our Outside Accountants to be our Chief Accounting Officer.
Paperwork on all customer invoices, credit card payments and check payments received at Corporate are copied and forwarded to Outside Accountants. Customer invoices are recorded daily. Customer payments received are recorded daily. Customer payments are reconciled with the bank on a daily basis. Aged Accounts Receivable Reports are sent to Corporate by the Outside Accountants with suggestions on a regular basis.
~~All bank accounts are reconciled monthly.~~
~~Financial Statements are prepared and reviewed monthly.~~

● All billing invoices prepared by the billing department are sent to the Outside Accountant for review and approval before sending out to the customer.
● Copies of all incoming payable invoices are sent to the Outside Accountant for review, approval and data entry into the accounting system. That way Corporate Office has the originals and the outside accountants have duplicate copies. Accounts Payable Aging Report is sent once a week from the Outside Accountants to the Corporate office. The Corporate office, along with Outside Accountants, decide on which bills to pay weekly. Electronic payments have a duel control approval system (one person is initiating the payment and another person is approving the payment). We also appointed the principle from our Outside Accountants to be our Chief Accounting Officer.
● Paperwork on all customer invoices, credit card payments and check payments received at Corporate are copied and forwarded to Outside Accountants. Customer invoices are recorded daily. Customer payments received are recorded daily. Customer payments are reconciled with the bank on a daily basis. Aged Accounts Receivable Reports are sent to Corporate by the Outside Accountants with suggestions on a regular basis.
● All bank accounts are reconciled monthly.
● Financial Statements are prepared and reviewed monthly.
The Company plans to further augment its addressing of material weaknesses, on an as-needed basis, by hiring additional accounting personnel once its initial corrective steps have been fully implemented, tested and found to be effective.
28
- 22 -

ADVANZEON SOLUTIONS, INC.
PART II-OTHER INFORMATION
Item 1. Legal Proceedings
With the exception of the matter set forth below, all of the legal proceedings for the ~~nine-month~~three month period ended ~~September 30, 2019,~~March 31, 2020, are disclosed in our annual report on Form 10-K for the year ended December 31, ~~2018,~~2019, filed on ~~May 24, 2019.~~April 9, 2020.
The Company previously reported that the litigation between Rotech Healthcare, Inc. and Pharmacy Value Management Solutions, Inc. settled. The Company rejected the draft settlement terms and continues to aggressively defend this litigation.
Item 1A. Risk Factors
The risk factors included in our Annual Report on Form 10-K for the year ended December 31, ~~2018~~2019 have not materially changed.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
With the exception of the matter set forth below, the sale of unregistered securities for the ~~nine~~three month period ended ~~September 30, 2019~~March 31, 2020 were disclosed in our annual report on Form 10-K for the year ended December 31, ~~2018,~~2019, filed on ~~May 24, 2019.~~April 9, 2020.
On May 1, 2019, we issued a convertible promissory note in the principle amount of $50,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 100,000 shares of the Company’s common stock at an exercise price of $0.15 per share.
On May 8, 2019, we issued a convertible promissory note in the principle amount of $50,250 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 105,000 shares of the Company’s common stock at an exercise price of $0.15 per share.
29
~~ADVANZEON SOLUTIONS, INC.~~
On May 21, 2019, we issued a convertible promissory note in the principle amount of $50,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 100,000 shares of the Company’s common stock at an exercise price of $0.15 per share.
~~On May~~March 22, 2019, we issued a convertible promissory note in the principle amount of $50,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 100,000 shares of the Company’s common stock at an exercise price of $0.15 per share.
On May 22, 2019, we issued a convertible promissory note in the principle amount of $15,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 30,000 shares of the Company’s common stock at an exercise price of $0.15 per share.
30
~~ADVANZEON SOLUTIONS, INC.~~
On May 30, 2019, we issued a convertible promissory note in the principle amount of $50,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 100,000 shares of the Company’s common stock at an exercise price of $0.15 per share.
On May 31, 2019, we issued a convertible promissory note in the principle amount of $150,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 300,000 shares of the Company’s common stock at an exercise price of $0.15 per share.
On June 12, 2019, we issued a convertible promissory note in the principle amount of $100,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 200,000 shares of the Company’s common stock at an exercise price of $0.15 per share.
On June 19, 2019, we issued a convertible promissory note in the principle amount of $25,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 50,000 shares of the Company’s common stock at an exercise price of $0.15 per share.
31
~~ADVANZEON SOLUTIONS, INC.~~
On June 24, 2019, we issued a convertible promissory note in the principle amount of $25,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 50,000 shares of the Company’s common stock at an exercise price of $0.15 per share.
On June 27, 2019, we issued a convertible promissory note in the principle amount of $25,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 50,000 shares of the Company’s common stock at an exercise price of $0.15 per share.
On July 1, 2019, we issued a convertible promissory note in the principle amount of $25,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 50,000 shares of the Company’s common stock at an exercise price of $0.15 per share.
32
~~ADVANZEON SOLUTIONS, INC.~~
On July 1, 2019, we issued a convertible promissory note in the principle amount of $25,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 50,000 shares of the Company’s common stock at an exercise price of $0.15 per share.
On July 1, 2019, we issued a convertible promissory note in the principle amount of $25,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 50,000 shares of the Company’s common stock at an exercise price of $0.15 per share.
On July 2, 2019, we issued a convertible promissory note in the principle amount of $25,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 50,000 shares of the Company’s common stock at an exercise price of $0.15 per share.
33
~~ADVANZEON SOLUTIONS, INC.~~
On July 2, 2019, we issued a convertible promissory note in the principle amount of $25,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 50,000 shares of the Company’s common stock at an exercise price of $0.15 per share.
On July 2, 2019, we issued a convertible promissory note in the principle amount of $25,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 50,000 shares of the Company’s common stock at an exercise price of $0.15 per share.
On July 2, 2019, we issued a convertible promissory note in the principle amount of $125,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 250,000 shares of the Company’s common stock at an exercise price of $0.15 per share.
On July 2, 2019, we issued a convertible promissory note in the principle amount of $25,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 50,000 shares of the Company’s common stock at an exercise price of $0.15 per share.
34
~~ADVANZEON SOLUTIONS, INC.~~
On July 3, 2019, we issued a convertible promissory note in the principle amount of $25,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 50,000 shares of the Company’s common stock at an exercise price of $0.15 per share.
On July 3, 2019, we issued a convertible promissory note in the principle amount of $100,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 200,000 shares of the Company’s common stock at an exercise price of $0.15 per share.
On July 5, 2019, we issued a convertible promissory note in the principle amount of $25,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 50,000 shares of the Company’s common stock at an exercise price of $0.15 per share.
35
~~ADVANZEON SOLUTIONS, INC.~~
On July 5, 2019, we issued a convertible promissory note in the principle amount of $50,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 100,000 shares of the Company’s common stock at an exercise price of $0.15 per share.
On July 8, 2019, we issued a convertible promissory note in the principle amount of $25,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 50,000 shares of the Company’s common stock at an exercise price of $0.15 per share.
On July 10, 2019, we issued a convertible promissory note in the principle amount of $50,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 100,000 shares of the Company’s common stock at an exercise price of $0.15 per share.
36
~~ADVANZEON SOLUTIONS, INC.~~
On July 10, 2019, we issued a convertible promissory note in the principle amount of $25,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 50,000 shares of the Company’s common stock at an exercise price of $0.15 per share.
On July 11, 2019, we issued a convertible promissory note in the principle amount of $30,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 60,000 shares of the Company’s common stock at an exercise price of $0.15 per share.
On July 11, 2019, we issued a convertible promissory note in the principle amount of $25,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 50,000 shares of the Company’s common stock at an exercise price of $0.15 per share.
On July 12, 2019, we issued a convertible promissory note in the principle amount of $25,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 50,000 shares of the Company’s common stock at an exercise price of $0.15 per share.
37
~~ADVANZEON SOLUTIONS, INC.~~
On July 17, 2019, we issued a convertible promissory note in the principle amount of $50,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 100,000 shares of the Company’s common stock at an exercise price of $0.15 per share.
On July 19, 2019, we issued a convertible promissory note in the principle amount of $50,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 100,000 shares of the Company’s common stock at an exercise price of $0.15 per share.
On August 24, 2019, we issued a convertible promissory note in the principle amount of $50,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 100,000 shares of the Company’s common stock at an exercise price of $0.15 per share.
38
~~ADVANZEON SOLUTIONS, INC.~~
On August 24, 2019, we issued a convertible promissory note in the principle amount of $200,000 to an accredited investor. The interest rate was 12%. The Holder of the note has the right to convert all or a portion of the principle and any accrued interest into shares of our common stock at a per share price equal to the lesser of (i) 15% below the average daily closing price of our common stock for the immediately preceding twenty (20) business days or (ii) $0.11. The principal amount and any accrued but unpaid interest under the note shall be due and payable on the earliest to occur (i) the date which is twelve months from the effective date of the note or (ii) the receipt by the Company of payment on its account receivable owed to it by Universal Health Care, Inc. and Universal Health Care Insurance Company, which accounts receivable is currently being processed in the matter of The Receivership of Universal Health Care, Inc., a Florida corporation and The Receivership of Universal Health Care Insurance Company, Inc., a Florida corporation under case numbers 2013-CA and 2013-CA, respectively. The Company also granted to the purchaser a five-year warrant to purchase 400,000 shares of the Company’s common stock at an exercise price of $0.15 per share.
All of the convertible promissory notes listed above were issued to accredited investors, as that term is defined under the Section 501 of Regulation D, promulgated under the Securities Act of 1933, as amended. The warrants issued in connection with the promissory notes all have a cashless exercise feature.
~~On May 1, 2019,~~2020, we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.
On ~~May 1, 2019,~~March 31, 2020, we issued ~~50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.~~
~~On May 10, 2019, we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.~~
~~On May 11, 2019, we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.~~
~~On May 19, 2019, we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.~~
~~On May 22, 2019, we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.~~
~~On May 28, 2019, we issued 3,000,000 warrants to our Chief Accounting Officer. The warrants have a term of five years and an exercise price of $0.0650 per warrant.~~
39
~~ADVANZEON SOLUTIONS, INC.~~
~~On May 30, 2019, we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.~~
~~On May 31, 2019, we issued 638,888~~169,551 warrants to our Chief Executive Officer in lieu of ~~2019~~2020 first quarter salary. The warrants have a term of five years and an exercise price of ~~$0.09~~$0.39 per warrant.
~~On May 31, 2019, we issued 347,222 warrants to our President in lieu of 2019 first quarter salary. The warrants have a term of five years and an exercise price of $0.09 per warrant.~~
~~On June 03, 2019, we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.~~
~~On June 06, 2019, we issued 50,000 warrants to a member of our Dental Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.~~
~~On June 08, 2019, we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.~~
~~On June 08, 2019, we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.~~
~~On June 11, 2019, we issued 50,000 warrants to a member of our Dental Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.~~
~~On June 12, 2019, we issued 1,000,000 warrants to a member of our contracted supplier. The warrants have a term of five years and an exercise price of $0.11 per warrant.~~
~~On June 14, 2019, we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.~~
~~On June 20, 2019, we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.~~
~~On June 22, 2019, we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.~~
~~On June 24, 2019, we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.~~
40
~~ADVANZEON SOLUTIONS, INC.~~
~~On June 24, 2019, we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.~~
~~On June 25, 2019, we issued 718,750 warrants to our Chief Executive Officer in lieu of 2019 second quarter salary. The warrants have a term of five years and an exercise price of $0.08 per warrant.~~
~~On June 25, 2019, we issued 390,625 warrants to our consultant in lieu of 2019 second quarter salary. The warrants have a term of five years and an exercise price of $0.08 per warrant.~~
~~On June 27, 2019, we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.~~
~~On June 30, 2019, we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.~~
~~On June 30, 2019, we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.~~
~~On July 1, 2019, we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.~~
~~On July 1, 2019, we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.~~
~~On July 1, 2019, we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.~~
~~On July 1, 2019, we issued 50,000 warrants to a member of our Dental Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.~~
~~On July 6, 2019, we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.~~
~~On July 11, 2019, we issued 50,000 warrants to a member of our Dental Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.~~
~~On July 25, 2019, we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.~~
41
~~ADVANZEON SOLUTIONS, INC.~~
~~On August 19, 2019, we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.~~
~~On August 31, 2019, we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.~~
~~On September 25, 2019, we issued 50,000 warrants to a member of our Medical Advisory Board, an accredited investor. The warrants have a term of three years and an exercise price of $0.25 per warrant.~~
On September 30, 2019, we issued 136,905 warrants to our Chief Executive Officer in lieu of 2019 third quarter salary. The warrants have a term of five years and an exercise price of $0.42 per warrant.
~~On September 30, 2019, we issued 62,500 warrants to our consultant in lieu of 2019 third quarter salary. The warrants have a term of five years and an exercise price of $0.42 per warrant.~~
We relied on Section 4 (2) of the Securities Act of 1933, as amended and or Section 501 of Regulation D promulgated under said Act as the exemption from registration under the Act.
Item 3. Exhibits
Documents filed as part of this Report.
Exhibit 31.1 Certification of Clark A. Marcus pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Exhibit 31.2 Certification of ~~Arnold B. Finestone~~Lloyd K. Marcus pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
Exhibit 32.1 Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Exhibit 32.2 Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Exhibit 10.0 Current Report on Form 8-K dated April 27, 2020
42
- 23 -


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


Advanzeon Solutions, Inc.

Registrant

Date: ~~November 13, 2019~~May 19, 2020 By: /s/ Clark A. Marcus
Clark A. Marcus,
Chief Executive Officer

Date: ~~November 13, 2019~~May 19, 2020 By: /s/ ~~Arnold B. Finestone~~Lloyd K. Marcus
~~Arnold B. Finestone~~
~~President and~~ Lloyd K. Marcus,
Chief ~~Financial~~Accounting Officer

- 24 -
43

Delaware		95-2594724
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☐	Smaller reporting company ☒
	Emerging growth company ☐

		Pages
PART I.	Financial Information
Item 1.	Consolidated Financial Statements
	Consolidated Balance Sheets as of ~~September 30, 2019~~March 31, 2020 (unaudited) and December 31, ~~2018~~2019	41 - 52
	Consolidated Statements of Operations for the Three ~~and Nine~~ Month Periods Ended ~~September 30,~~March 31, 2020 and 2019 ~~and 2018~~ (unaudited)	63
	Consolidated Statement of ~~Stockholders'~~Stockholders’ Deficiency For the ~~Nine~~Three Month Period Ended ~~September 30, 2019~~March 31, 2020 (unaudited) and at December 31, ~~2018~~2019	74
	Consolidated Statements of Cash Flows for the ~~Nine~~Three Month Periods Ended ~~September 30,~~March 31, 2020 and 2019 ~~and 2018~~ (unaudited)	85
	Notes to Consolidated Financial Statements	96 - 1714
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	1815 - 2620
Item 3.	Quantitative and Qualitative Disclosure about Market Risk	2721
Item 4.	Controls and Procedures	2721 - 2822
PART II.	Other Information
Item 1.	Legal Proceedings	2923
Item 1A.	Risk Factors	2923
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	~~29 - 42~~23
Item 3.	Exhibits	42
		23

LIABILITIES AND STOCKHOLDERS’ DEFICIENCY

	March 31, 2020			December 31,
	(unaudited)			2019
CURRENT LIABILITIES
Related party loans payable	$	257,729		$	342,670
Account payable		309,003			99,441
Debt		12,534,189			12,352,189
Contingent liability		642,659			642,659
Current portion of lease liability		94,410			113,911
Other accrued expenses		16,321,871			15,891,787
Total current liabilities		30,159,861			29,442,657

LEASE LIABILITY, NET OF CURRENT PORTION		121,322			146,880

TOTAL LIABILITIES		30,281,183			29,589,537

STOCKHOLDERS’ DEFICIENCY
Preferred stock, $.001 par value; 1,000,000 shares authorized, as of March 31, 2020 and December 31, 2019		-			-
Series C Convertible Preferred; $.001 par value; 14,400 shares authorized; 10,434 shares issued and outstanding as of March 31, 2020 and December 31, 2019		10			10
Series D Convertible Preferred; $.001 par value; 7,000 shares authorized; 250 shares issued issued and outstanding as of March 31, 2020 and December 31, 2019		-			-
Remaining Preferred stock; $.001 par value; 978,600 shares as of March 31, 2020 and December 31, 2019		-			-
Common stock, $0.01 par value; 1,000,000,000 shares authorized; 71,661,656 shares issued and outstanding as of March 31, 2020 and December 31, 2019		716,617			716,617
Additional paid in capital		28,719,246			28,719,246
Accumulated deficit		(58,766,033	)		(57,837,687	)
Total stockholders’ deficiency		(29,330,160	)		(28,401,814	)

TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIENCY	$	951,023		$	1,187,723

ASSETS	ASSETS

		September 30, 2019		December 31,		March 31, 2020		December 31,
		(unaudited)		2018		(unaudited)		2019
CURRENT ASSETS
Cash		$	64,057	$	25,036	$	14,874	$	69,327
Accounts receivable			25,171		24,890		47,340		29,769
Current portion of right of use asset			124,311		53,634		94,410		113,911
Other current assets			2,354,854		828,996		667,082		826,597
Total current assets			2,568,393		932,556		823,706		1,039,604

PROPERTY, PLANT, AND EQUIPMENT
Property and equipment, net			1,324		—		5,995		1,239
Leasehold improvements, net			—		299
Total property, plant, and equipment			1,324		299		5,995		1,239

RIGHT OF USE ASSET, NET OF CURRENT PORTION			171,885		28,920		121,322		146,880

TOTAL ASSETS		$	2,741,602	$	961,775	$	951,023	$	1,187,723

LIABILITIES AND STOCKHOLDERS' DEFICIENCY

		September 30, 2019			December 31,
		(unaudited)			2018
CURRENT LIABILITIES
Related party loans payable	$	444,920		$	737,023
Account payable		1,423,284			700,067
Debt		12,163,189			10,087,939
Contingent liability		642,659			642,659
Current portion of lease liability		124,311			53,634
Other accrued expenses		15,734,145			14,614,772
Total current liabilities		30,532,508			26,836,094

LEASE LIABILITY, NET OF CURRENT PORTION		171,885			28,920

TOTAL LIABILITIES		30,704,393			26,865,014

STOCKHOLDERS' DEFICIENCY
Preferred stock, $.001 par value; 1,000,000
shares authorized, as of September 30, 2019
and December 31, 2018		—			—
Series C Convertible Preferred; $.001 par value;
14,400 shares authorized; 10,434 shares
issued and outstanding as of September 30, 2019
and December 31, 2018		10			10
Series D Convertible Preferred; $.001 par value;
7,000 shares authorized; 250 shares issued
and outstanding as of September 30, 2019
and December 31, 2018		—			—
Remaining Preferred stock; $.001 par value;
978,600 shares as of September 30, 2019
and December 31, 2018		—			—
Common stock, $0.01 par value; 1,000,000,000
shares authorized; 67,361,656 and 66,661,656
shares issued and outstanding as of
Septmeber 30, 2019 and December 31, 2018		673,617			666,617
Additional paid in capital		28,036,007			28,012,007
Accumulated deficit		(56,672,425	)		(54,581,873	)
Total stockholders' deficiency		(27,962,791	)		(25,903,239	)

TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIENCY	$	2,741,602		$	961,775

	Three-Month Period Ended
	March 31,
	2020			2019

Revenues:
Obstructive sleep apnea (OSA)	$	127,548			67,923
Total revenues		127,548			67,923

Costs and expenses:
Costs of revenues		64,909			41,660
General and administrative		596,065			425,804
Depreciation and amortization		311			205
Total costs and expenses		661,285			467,669

Loss from operations		(533,737	)		(399,746	)

Other income (expense):
Interest expense		(394,629	)		(328,015	)
Interest income		20			-
Total other income (expense)		(394,609	)		(328,015	)

Income taxes		-			-

Net loss	$	(928,346	)	$	(727,761	)

PER SHARE INFORMATION
Net Loss Per Common Share	$	(0.01	)	$	(0.01	)

Weighted Average Number of Common Shares Outstanding		71,661,656			69,690,545

	Series C		Series C
	Convertible		Convertible		Common
	Preferred		Preferred		Stock		Common		Additional
	Stock Number		Stock		Stock Number		Stock		Paid-in		Accumulated
	of Shares		Amount		of Shares		Amount		Capital		Deficit			Total

Balance at December 31, 2019		10,434	$	10		71,661,656	$	716,617	$	28,719,246	$	(57,837,687	)	$	(28,401,814	)

Net loss		-		-		-		-		-		(928,346	)		(928,346	)

Balance at March 31, 2020		10,434	$	10		71,661,656	$	716,617	$	28,719,246	$	(58,766,033	)	$	(29,330,160	)

	Three-Month Period Ended						Nine-Months Period Ended
	September 30,						September 30,
	2019			2018			2019			2018
Revenues:
Obstructive sleep apnea (OSA)	$	68,173		$	99,083		$	226,549			449,650
Total revenues		68,173			99,083		��	226,549			449,650
Costs and expenses:
Costs of revenues		2,394			46,028			110,211			280,372
General and administrative		428,077			409,419			1,269,920			1,396,478
Depreciation and amortization		84			149			524			449
Total costs and expenses		430,555			455,596			1,380,655			1,677,299
Loss from operations		(362,382	)		(356,513	)		(1,154,106	)		(1,227,649	)
Other income (expense):
Interest expense		(383,798	)		(307,922	)		(1,052,991	)		(1,148,795	)
Interest income		29			—			6,023			—
Legal settlement		—			—			112,172			328,269
State tax penalty		(1,650	)		—			(1,650	)		—
Extinguishment of loan due to shareholder		—			—			—			7,771,140
Settlement of prior accounting services		—			—			—			(240,000	)
Other income		—			—			—			2,380
Total other income (expense)		(385,419	)		(307,922	)		(936,446	)		6,712,994
Income taxes		—			—			—			—
Net (loss) income	$	(747,801	)	$	(664,435	)	$	(2,090,552	)	$	5,485,345
PER SHARE INFORMATION
Net (Loss) Income Per Common Share	$	(0.01	)	$	(0.01	)	$	(0.03	)	$	0.08
Weighted Average Number of Common
Shares Outstanding		67,361,656			66,661,656			67,140,411			65,849,175

	Nine Month Periods Ended
	September 30,
	2019			2018
CASH FLOWS FROM OPERATING ACTIVITIES
Net (loss) income	$	(2,090,552	)	$	5,485,345
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Depreciation and amortization		524			449
Stock issued for services		16,000			240,000
Extinguishment of loan due to shareholder
and accrued interest		—			(7,771,140	)
Amortization of right of use assets		62,135			—
Net changes in assets and liabilities:
Accounts receivable		(281	)		(34,493	)
Other current assets		(1,525,858	)		(700,842	)
Payments on lease liabilities		(62,135	)		—
Accounts payable		431,114			520,379
Contingent liability		—			152,664
Accrued interest - related party		—			(246,568	)
Other accrued expenses		1,119,373			1,328,842
Net cash used in operating activities		(2,049,680	)		(1,025,364	)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property, plant, and equipment		(1,549	)		—
Net cash used in investing activities		(1,549	)		—
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from promissory notes		2,100,250			1,079,223
Payments on debt		(25,000	)		—
Sale of stock		15,000			—
Net cash provided by financing activities		2,090,250			1,079,223
Net increase in cash		39,021			53,859
CASH - Beginning of Year		25,036			18,200
CASH - END OF PERIOD	$	64,057		$	72,059
Supplemental disclosures of cash flow information:
Cash paid during the period for:
Interest	$	6,960		$	—
Income taxes	$	—		$	—
Recording of right of use assets under
lease agreements (ASU 2016-02)	$	390,260		$	—
Schedule of non-cash investing transactions:
Convertible promissory note converted to common stock	$	—		$	51,231

	September 30, 2019		December 31, 2018

Due from escrow account	$	1,918,898	$	472,788
Loans to others		22,459		—
Security deposit		5,500		13,500
Capitalized portion of lease		2,094		2,951
Prepaid expenses		71,394		5,248
Miscellaneous receivable		334,509		334,509

Other current asset	$	2,354,854	$	828,996

Total present value of right of use assets
under lease agreements	$	390,260

Amortization of right of use assets		(94,064	)

Total right of use assets as of September 30, 2019	$	296,196

Total future minimum lease payments	$	317,251

Less present value discount		21,055

Total right of use lease liabilities as of September 30, 2019		296,196

Less current portion due within one year		124,311

Long-term right of use liabilities	$	171,885

	2019		2018		Change			Percent Change

Parent	$	118,096	$	130,218	$	(12,122	)		-9.31	%
PVMS		309,981		279,201		30,780			11.02	%

Total	$	428,077	$	409,419	$	18,658			4.56	%

							Percent
	2020		2019		Change		Change

Parent	$	243,222	$	196,135	$	47,087		24.01	%
PVMS		352,843		229,669		123,174		53.63	%

Total	$	596,065	$	425,804	$	170,261		39.99	%

2019	$	1,052,991
2018		1,148,795
Change	$	(95,804	)
Percentage Change		-8.34	%

	Advanzeon Solutions, Inc.

	Registrant

Date: ~~November 13, 2019~~May 19, 2020	By:	/s/ Clark A. Marcus
		Clark A. Marcus,
		Chief Executive Officer


Date: ~~November 13, 2019~~May 19, 2020	By:	/s/ ~~Arnold B. Finestone~~Lloyd K. Marcus
		~~Arnold B. Finestone~~ ~~President and~~ Lloyd K. Marcus,
		Chief ~~Financial~~Accounting Officer